Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024)
Inhibikase Therapeutics (IKT) has disclosed Asset Utilization Ratio for 4 consecutive years, with 0.0 as the latest value for Q3 2024.
- On a quarterly basis, Asset Utilization Ratio fell 100.0% to 0.0 in Q3 2024 year-over-year; TTM through Sep 2024 was 0.0, a 100.0% decrease, with the full-year FY2023 number at 0.01, up 260.65% from a year prior.
- Asset Utilization Ratio was 0.0 for Q3 2024 at Inhibikase Therapeutics, down from 0.01 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.14 in Q1 2021 to a low of 0.0 in Q3 2024.
- A 4-year average of 0.03 and a median of 0.02 in 2024 define the central range for Asset Utilization Ratio.
- Peak YoY movement for Asset Utilization Ratio: soared 715.42% in 2023, then tumbled 100.0% in 2024.
- Inhibikase Therapeutics' Asset Utilization Ratio stood at 0.07 in 2021, then tumbled by 93.43% to 0.0 in 2022, then soared by 248.72% to 0.02 in 2023, then crashed by 100.0% to 0.0 in 2024.
- Per Business Quant, the three most recent readings for IKT's Asset Utilization Ratio are 0.0 (Q3 2024), 0.01 (Q2 2024), and 0.02 (Q1 2024).